J.P. Morgan Keeps 'Overweight' on Gilead Sciences

Analyst David Molowa thinks Gilead's HIV drug will receive approval by July 3

J.P. Morgan reiterates overweight on Gilead Sciences (GILD ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.